Previous 10 | Next 10 |
2024-01-30 17:23:08 ET More on IceCure Medical IceCure Medical Ltd (ICCM) Q3 2023 Earnings Call Transcript IceCure shares rally 53% on ProSense kidney cancer study IceCure stock climbs 10% amid FDA appeal, earnings report Seeking Alpha’s Quant Rating o...
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer PR Newswire IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of p...
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class PR Newswire IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in Ca...
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation PR Newswire ProSense® users speaking at the conference about cryoablation included ISVIR Presiden...
2024-01-12 16:08:39 ET More on IceCure Medical IceCure shares rally 53% on ProSense kidney cancer study IceCure stock climbs 10% amid FDA appeal, earnings report For further details see: IceCure Medical regains compliance with Nasdaq
CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tum...
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results PR Newswire U.S. sales contin...
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response PR Newswire Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evid...
Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients" PR Newswire Independent study published in Annals of Surgical Oncology concludes cryoablation is an oncologica...
2023-12-01 08:25:56 ET Losers: Smart for Life ( SMFL ) -38% announces exercise of warrants for $1.5 Million gross proceeds . Ampio Pharmaceuticals ( AMPE ) -34% . Incannex Healthcare ( IXHL ) -34% . Vivos Therapeutics ( VVOS ) -14% . ...
News, Short Squeeze, Breakout and More Instantly...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 PR Newswire Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel , ...
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function PR Newswire ICESECRET interim results, as previously announced, dem...